Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2016 UBS Global Healthcare Conference on Wednesday, May 25, 2016 at 9:00 a.m. Eastern Time at the Grand Hyatt New York.

A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are advancing an innovative pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation (IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader in the IBS-C/CIC category, and we are applying our proven R&D and commercial capabilities to advance multiple internally-developed and externally-accessed product opportunities. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160518006344/en/

Ironwood Pharmaceuticals, Inc.
Media Relations
Trista Morrison, 617-374-5095
Director, Corporate Communications
[email protected]
or
Investor Relations
Mary T. Conway, 617-768-2628
Investor Relations
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

You May Also Be Interested In

• California Pool Partners Launches Owner-Centric Platform as Alternative to Traditional Private Equity Roll-Ups
• Michelin Unveils MICHELIN BIBTRACK Agricultural Tracks at Farm Progress
• Registered Agents Inc Is Getting Into the Registry Game